Dr. Reddy's gets DCGI nod for Zytorvi® in esophageal cancer

Dr. Reddy's gets DCGI nod for Zytorvi® in esophageal cancer — Dr. Reddy's Laboratories has received DCGI approval for Zytorvi® (toripalimab) for advanced esophageal squamous cell carcinoma, its second approved indication in India. This expands the drug’s market potential in oncology. The approval strengthens Dr. Reddy’s position in the immuno-oncology space.

📊 STOCKS: $DRREDDY | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #Approval